CLO23-043: Optimal Interval Between Immune Therapy and Targeted Therapy With Sotorasib in Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer
Journal of The National Comprehensive Cancer Network(2023)
摘要
"CLO23-043: Optimal Interval Between Immune Therapy and Targeted Therapy With Sotorasib in Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer" published on 31 Mar 2023 by National Comprehensive Cancer Network.
更多查看译文
关键词
kras g12c mutant non–small,sotorasib,targeted therapy,immune therapy,cancer
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要